EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

Cassandra M J Wannan, Barnaby Nelson, Jean Addington, Kelly Allott iD, Alan Anticevic, Celso Arango, Justin T Baker, Carrie E Bearden iD, Tashrif Billah, Sylvain Bouix, Matthew R Broome, Kate Buccilli und 48 weitere

Schizophrenia Bulletin · 30.04.2024 · 50 (3) · 496-512

DOI: 10.1093/schbul/sbae011 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Schizophrenia Bulletin, online erschienen am 07.03.2024. Verfasst von Cassandra M J Wannan und 59 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia. Hauptthemen laut MEDLINE: Psychotic Disorders, Schizophrenia. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS, Medical Research Council, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This article describes the rationale, aims, and methodology of the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ). This is the largest international collaboration to date that will develop algorithms to predict trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the development and use of novel pharmacological interventions for CHR individuals. We present a description of the participating research networks and the data processing analysis and coordination center, their processes for data harmonization across 43 sites from 13 participating countries (recruitment across North America, Australia, Europe, Asia, and South America), data flow and quality assessment processes, data analyses, and the transfer of data to the National Institute of Mental Health (NIMH) Data Archive (NDA) for use by the research community. In an expected sample of approximately 2000 CHR individuals and 640 matched healthy controls, AMP SCZ will collect clinical, environmental, and cognitive data along with multimodal biomarkers, including neuroimaging, electrophysiology, fluid biospecimens, speech and facial expression samples, novel measures derived from digital health technologies including smartphone-based daily surveys, and passive sensing as well as actigraphy. The study will investigate a range of clinical outcomes over a 2-year period, including transition to psychosis, remission or persistence of CHR status, attenuated positive symptoms, persistent negative symptoms, mood and anxiety symptoms, and psychosocial functioning. The global reach of AMP SCZ and its harmonized innovative methods promise to catalyze the development of new treatments to address critical unmet clinical and public health needs in CHR individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Psychotic DisordersSchizophreniaHumansProspective StudiesAdultProdromal SymptomsYoung AdultInternational CooperationAdolescentResearch DesignMaleFemale

Stichwörter der Autor:innen

clinical high riskconsortiumearly detectionpredictionpreventionpsychosis

Autor:innen und Institutionen

  • Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia.
  • Orygen, Parkville, VIC, Australia.
  • Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
  • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
  • Connecticut Mental Health Center, New Haven, CT, USA.
  • Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, CIBERSAM, Instituto de Salud Carlos III, School of Medicine, Universidad…

ORCID-Profile: Kelly Allott, Carrie E Bearden, Kristin S Cadenhead, Monica E Calkins, Guillermo Cecci, Covadonga M Diaz-Caneja, Dominic Dwyer, Joseph Kambeitz, John M Kane, Sung-Wan Kim, Jun Soo Kwon, Vijay A Mittal

Förderung

  • NIMH NIH HHS
  • Medical Research Council
  • Wellcome Trust

Zitieren

APA

Wannan, C. M. J., Nelson, B., Addington, J., Allott, K., Anticevic, A., Arango, C., Baker, J. T., Bearden, C. E., Billah, T., Bouix, S., Broome, M. R., Buccilli, K., Cadenhead, K. S., Calkins, M. E., Cannon, T. D., Cecci, G., Chen, E. Y. H., Cho, K. I. K., Choi, J., …, & Perkins, D. O. (2024). Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin, 50(3), 496-512. https://doi.org/10.1093/schbul/sbae011

Vancouver

Wannan CMJ, Nelson B, Addington J, Allott K, Anticevic A, Arango C, et al. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin. 2024;50(3):496-512. doi:10.1093/schbul/sbae011

BibTeX
@article{Wannan2024,
  author = {Wannan, Cassandra M J and Nelson, Barnaby and Addington, Jean and Allott, Kelly and Anticevic, Alan and Arango, Celso and Baker, Justin T and Bearden, Carrie E and Billah, Tashrif and Bouix, Sylvain and Broome, Matthew R and Buccilli, Kate and Cadenhead, Kristin S and Calkins, Monica E and Cannon, Tyrone D and Cecci, Guillermo and Chen, Eric Yu Hai and Cho, Kang Ik K and Choi, Jimmy and Clark, Scott R and Coleman, Michael J and Conus, Philippe and Corcoran, Cheryl M and Cornblatt, Barbara A and Diaz-Caneja, Covadonga M and Dwyer, Dominic and Ebdrup, Bjørn H and Ellman, Lauren M and Fusar-Poli, Paolo and Galindo, Liliana and Gaspar, Pablo A and Gerber, Carla and Glenthøj, Louise Birkedal and Glynn, Robert and Harms, Michael P and Horton, Leslie E and Kahn, René S and Kambeitz, Joseph and Kambeitz-Ilankovic, Lana and Kane, John M and Kapur, Tina and Keshavan, Matcheri S and Kim, Sung-Wan and Koutsouleris, Nikolaos and Kubicki, Marek and Kwon, Jun Soo and Langbein, Kerstin and Lewandowski, Kathryn E and Light, Gregory A and Mamah, Daniel and Marcy, Patricia J and Mathalon, Daniel H and McGorry, Patrick D and Mittal, Vijay A and Nordentoft, Merete and Nunez, Angela and Pasternak, Ofer and Pearlson, Godfrey D and Perez, Jesus and Perkins, Diana O},
  title = {Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis},
  journal = {Schizophrenia Bulletin},
  year = {2024},
  volume = {50},
  number = {3},
  pages = {496--512},
  doi = {10.1093/schbul/sbae011}
}
Kostenlos starten →